유지희 교수

Glycosylated hemoglobin (HbA1c) has been the sole surrogate marker for assessing diabetic complications. However, consistently reported limitations of HbA1c are that it lacks detailed information on short-term glycemic control and can be easily interfered with by various clinical conditions such as anemia, pregnancy, or liver disease. Thus, HbA1c alone may not represent the real glycemic status of a patient. The advancement of continuous glucose monitoring (CGM) has enabled both patients and hea

Continuous glucose monitoring (CGM) technology has evolved over the past decade with the integration of various devices including insulin pumps, connected insulin pens (CIPs), automated insulin delivery (AID) systems, and virtual platforms. CGM has shown consistent benefits in glycemic outcomes in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) treated with insulin. Moreover, the combined effect of CGM and education have been shown to improve glycemic outcomes more than CGM a

Elevated HGI levels are independently associated with NAFLD in a healthy Asian population.

The use of dulaglutide was associated with a significant reduction in HbA1c and body weight over a 6-month period in a real-world clinical setting. T2D patients with higher baseline HbA1c concentrations were more likely to demonstrate good clinical responses to dulaglutide.

Previous studies have consistently demonstrated the positive effects of continuous glucose monitoring (CGM) on glycemic outcomes and complications of diabetes in people with type 1 diabetes. Guidelines now consider CGM to be an essential and cost-effective device for managing type 1 diabetes. As a result, insurance coverage for it is available. Evidence supporting CGM continues to grow and expand to broader populations, such as pregnant people with type 1 diabetes, people with type 2 diabetes tr

Increased mean HbA1c levels elevated the risk of incident NAFLD, even with NGT. Increases in visit-to-visit variability of HbA1c independently elevated the risk of incident NAFLD, but only in the diabetes group.

This corrects the article "Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control" in Volume 44 on page 828.

In well-controlled T1DM with MG ≤135 mg/dL, we suggest a %CV <31% to achieve the %TBR<54 mg/dL <1 target. Furthermore, we suggest a %CV <29.2% to achieve the target of %TBR<54 mg/dL =0 for people at high risk of hypoglycemia.

<b><i>Background:</i></b> We aimed to determine whether there are racial differences in glucose management indicator (GMI) equation for Asians and propose an adjusted GMI equation specific to Asians. <b><i>Methods:</i></b> This was a 24-week, prospective, observational study. A total of 106 Korean subjects with type 1 diabetes was included in the analyses. Continuous glucose monitoring (CGM: Dexcom G5) data and glycated hemoglobin (HbA1c) were obtained at the end of 3 months (<i>n</i> = 106) and

The GMI is overestimated in G6 users, particularly those with well-controlled diabetes, but the GMI and HbA_1c discordance improved with a revised equation from the observed data. The FL profile showed greater discordance for lower HbA_1c levels or higher HbA_1c levels.

We evaluated the effectiveness of the predictive low-glucose suspend (PLGS) algorithm in the DIA:CONN G8. Forty people with type 1 diabetes mellitus (T1DM) who used a DIA:CONN G8 for at least 2 months with prior experience using pumps without and with PLGS were retrospectively analyzed. The objective was to assess the changes in time spent in hypoglycemia (percent of time below range [%TBR]) before and after using PLGS. The mean age, sensor glucose levels, glucose threshold for suspension, and s

In adults with poorly controlled insulin-treated T2D, rt-CGM use with structured education significantly improved the HbA_1c and CGM metrics, primarily by reducing hyperglycemia, regardless of age.

We investigated the association between income parameters and the risk of type 2 diabetes (T2D) influenced by obesity. We analyzed the Korean National Health Insurance Service data (2002–2022), including 3,462,002 adults (aged ≥ 30 years) without diabetes who underwent health examinations in 2012. Income status was assessed annually from 2008 to 2012, and sustained income status was defined as maintaining the same income category for all five consecutive years. Hazard ratios (HRs) for incident T

The number of insulin users in Korea has doubled over the past 20 years. Numerous studies have shown the benefits of continuous glucose monitoring (CGM) on glycemic outcomes in people with diabetes receiving insulin therapy. However, patients often failed to reach the target even with the CGM. Advanced technology, such as automated insulin delivery (AID), can potentially reduce patient burden and improve glycemic status in people on insulin therapy. However, wearing a CGM all day and complex dev

Familial chylomicronemia syndrome (FCS) and homozygous familial hypercholesterolemia (HoFH) are rare genetic disorders characterized by profound dyslipidemia and high residual cardiovascular risk, for which conventional therapies have demonstrated limited efficacy. Recent advances in antisense oligonucleotide and small interfering RNA (siRNA)–based therapies targeting apolipoprotein CIII (APOC3) and angiopoietin-like protein 3 (ANGPTL3) have introduced promising treatment options. APOC3 inhibito